Who
Esther Rajavelu
Officer
Company insider
Files Form 4 as: CFO & Cbo, Spero Therapeutics; Chief Financial Officer, Fulcrum Therapeutics.
In numbers
- Trades disclosed
- 23
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $787K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 3 Jan 2022
- Last trade
- 4 May 2026
- Last filed
- 6 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 May 2026filed 6 May 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $63K25,240 at $2.51 | filing |
| 4 May 2026filed 6 May 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $63K25,240 at $2.51 | filing |
| 6 Feb 2026filed 9 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $88K37,101 at $2.36 | filing |
| 6 Feb 2026filed 9 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $120K50,816 at $2.36 | filing |
| 6 Feb 2026filed 9 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $88K37,101 at $2.36 | filing |
| 6 Feb 2026filed 9 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $120K50,816 at $2.36 | filing |
| 2 Feb 2026filed 4 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —249,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K18,442 at $2.20 | filing |
| 2 Feb 2026filed 4 Feb 2026 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —498,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —498,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —249,000 at $0.00 | filing |
| 2 Feb 2026filed 4 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K18,442 at $2.20 | filing |
| 7 Nov 2025filed 12 Nov 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $95K40,270 at $2.37 | filing |
| 2 May 2025filed 6 May 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 5 Feb 2025filed 5 Feb 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K20,689 at $0.78 | filing |
| 3 Feb 2025filed 5 Feb 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —266,139 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 8 Nov 2024filed 12 Nov 2024 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K17,245 at $1.30 | filing |
| 7 Nov 2024filed 12 Nov 2024 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $31K23,351 at $1.31 | filing |
| 1 Feb 2024filed 5 Feb 2024 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —119,866 at $0.00 | filing |
News
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare ConferenceSPRO · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Esther Rajavelu; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.